✦ LIBER ✦

Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer

✍ Scribed by Ganesan, Prasanth; Piha-Paul, Sarina; Naing, Aung; Falchook, Gerald; Wheler, Jennifer; Janku, Filip; Zinner, Ralph; Laday, Shell; Kies, Merrill; Tsimberidou, Apostolia M.

Book ID: 121089907
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 341 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-0013-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical trial of lenalidomide i

Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer

✍ Prasanth Ganesan, Sarina Piha-Paul, Aung Naing, Gerald Falchook, Jennifer Wheler 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 258 KB

Phase I study of temsirolimus in combina

Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors

✍ Alan H. Bryce, Ravi Rao, Jann Sarkaria, Joel M. Reid, Yingwei Qi, Rui Qin, C. Da 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 236 KB

Clinical Trial Experience With Temsiroli

Clinical Trial Experience With Temsirolimus in Patients With Advanced Renal Cell Carcinoma

✍ Gary R. Hudes; Anna Berkenblit; Jay Feingold; Michael B. Atkins; Brian I. Rini; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 634 KB

Phase I trial of ZD0473 in combination w

Phase I trial of ZD0473 in combination with vinorelbine for patients with advanced cancer

✍ J. Douillard; J. Cosaert; V. Barbarot 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 187 KB

Phase I clinical trial of bortezomib in

Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors

✍ David P. Ryan; Leonard J. Appleman; Thomas Lynch; Jeffrey G. Supko; Panagiotis F 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 2 views

## Abstract ## BACKGROUND. Bortezomib is the first proteasome inhibitor to show preliminary evidence of activity against solid tumors. Findings from preclinical studies prompted a Phase I trial to determine the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of bortezomib in combi

A phase I pharmacodynamic trial of borte

A phase I pharmacodynamic trial of bortezomib in combination with doxorubicin in patients with advanced cancer

✍ Noelle K. LoConte; James P. Thomas; Dona Alberti; Jennifer Heideman; Kimberly Bi 📂 Article 📅 2008 🏛 Springer 🌐 English ⚖ 326 KB